title: Effects of bunazosin on plasma glucose levels in hypertensive diabetic patients.
abstract: Twenty-nine hypertensive diabetic patients received 1.5 to 4.0 mg of bunazosin daily for three months. Both systolic and diastolic blood pressures were significantly reduced by the bunazosin treatment, while heart rate was unchanged. No significant changes were noted in fasting plasma glucose levels or in levels of hemoglobin A1c. Serum lipid levels remained unchanged during treatment. It is concluded that bunazosin does not adversely affect glucose metabolism or increase serum lipid levels in hypertensive diabetic patients.
authors.affiliation: Department of Internal Medicine, Aoto Hospital, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Takeda
authors.forename: T
authors.initials: T
authors.lastname: Iwai
authors.forename: A
authors.initials: A
authors.lastname: Tanamura
authors.forename: M
authors.initials: M
authors.lastname: Nagano
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000317:Adrenergic alpha-Antagonists; D001786:Blood Glucose; D011799:Quinazolines; C018176:bunazosin